News

News banner text

100 percent of mice treated with NTX-250 saw complete regression of tumors, long-term survival, and robust immune cell infiltration NTX-250 demonstrated translational potential in non-human primates by inducing HPV-specific immune responses EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented the first […]

EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the upcoming poster presentation of new preclinical data for its lead therapeutic candidate, NTX-0250, which targets human papillomavirus (HPV)-driven cancers. The company will present this data at the 37th annual meeting of the […]

Dr. Schott will oversee the advancement of Nutcracker Therapeutics’ oncology pipeline, helping to expand the company’s novel RNA therapeutics platform  The announcement follows several recent C-suite hires, adding significant pharmaceutical industry and drug development experience to Nutcracker Therapeutics’ executive team EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies […]

John Stubenrauch, Ph.D., joins as Chief Operating Officer The company also appointed Geoff Nosrati, Ph. D., as Chief Business Officer and Ian Wiener, J.D., as General Counsel Nutcracker Therapeutics reveals oncology-focused pipeline programs, with lead candidate in IND-enabling studies EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through […]

Emeryville, Calif. – March 14, 2022 Financing round led by returning investor ARCH Venture Partners Enables accelerated development of therapeutic pipeline built upon its proprietary RNA technology platform Industry veteran Michael F. Bigham appointed to the board of directors Nutcracker Therapeutics, Inc., a biotech company developing RNA therapeutics using its proprietary biochip-based manufacturing platform, today […]

Emeryville, Calif. – September 23, 2020 Financing led by ARCH Venture Partners Company aims to efficiently develop, manufacture and deliver mRNA medicines to patients worldwide using its proprietary push-button “GMP-in-a-box” system Company will initially focus on developing first-in-class mRNA therapeutics for oncology indications and forging collaborations with biotech and pharma companies Nutcracker Therapeutics, Inc., a […]

Emeryville, Calif. – September 23, 2020 – Nutcracker Therapeutics, Inc., a company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, today announced the appointment of Madhavan (“Madhu”) Balachandran, former executive vice president of operations at Amgen, as chief operating officer. Mr. Balachandran will oversee all operational aspects of the company including manufacturing […]